Critics Suggest FDA Approving Aduhelm Will Erode the “Public Trust”: What About Patients’ Trust?
FDA Law Blog
JUNE 23, 2021
In 2012 we at the Agency, under Dr. Janet Woodcock’s leadership, identified the need for more systematic patient engagement — a way to improve representativeness and be more proactive rather than reactive to interacting with patient communities. However, in the coming days we hope to do so and may provide our thoughts in subsequent posts.
52 
Let's personalize your content